Prioritizing Lp(a) Screening and LDL-C Lowering to Transform Cardiovascular Risk Across the ASCVD Continuum

CME Series on LDL-C, Lp(a), and ASCVD Risk

Watch Now

 

 

Program Title:

Prioritizing Lp(a) Screening and LDL-C Lowering to Transform Cardiovascular Risk Across the ASCVD Continuum

Session 1: Lp(a) and LDL-C: Why You Need to Address Both in ASCVD

Session 2: Lp(a) and LDL-C: Current and Future Management Strategies to Address Residual Risk in ASCVD

• Date: July 10th, 2025
• Program Expiration: July 10th, 2026

 

 

Program Info:

Session 1:

Emerging research highlights the impact of long-term exposure to elevated LDL-C on ASCVD risk and lipoprotein(a) (Lp[a]) as a risk enhancer for ASCVD. In this concise CME session, join lipid specialists Dr. Erin Michos and Dr. Pamela Morris to discuss how to optimize LDL-C lowering early and how to interpret Lp(a) levels and manage patients with elevated Lp(a). Lp[a]) has emerged as a significant, independent, and genetically determined risk enhancer for ASCVD by promoting inflammation and atherogenesis. Clinicians must be aware of  Lp(a) screening guidelines, recommended treatment options, and emerging pharmacotherapies targeting Lp(a) lowering that may soon be available.

Learning Objectives:

• Describe the impact of long-term exposure to elevated LDL-C on ASCVD risk 
• Explain the role of Lp(a) as a risk enhancer for and pathophysiological driver of ASCVD
• Summarize current recommendations and guidelines for LDL-C screening following an ASCVD-related event and universal screening for Lp(a)

 

Session 2:

While management with statin therapy has been the standard of care for the past several decades for patients with higher levels of low-density lipoprotein cholesterol (LDL-C), approximately 75% of patients with atherosclerotic cardiovascular disease (ASCVD) are not at LDL-C goal, and many are not on statin therapy .  Dr. Erin Michos and Dr. Pamela Morris present a call to action for clinicians to test all adults for lipoprotein(a) (Lp[a]) levels and to develop management strategies for those with elevated Lp(a) and/or LDL-C via lifestyle and pharmacotherapy interventions to lower ASCVD risk in this concise CME session. These experts discuss  the safety and efficacy of current and emerging therapies for LDL-C and Lp(a) reduction in high-risk patients.

Learning Objectives:

• Discuss the efficacy and safety of current and emerging therapies for the reduction of LDL-C and ASCVD risk
• Identify the safety and efficacy of current and emerging therapies for the reduction of Lp(a) in patients with ASCVD

 

 

Featured Speakers: